Literature DB >> 9371338

Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds.

Y Kashida1, M Kato.   

Abstract

Fluoroquinolone antibacterial agents have been reported to induce tendon lesions in juvenile rats. In the present study, we characterized fluoroquinolone-induced Achilles tendon lesions by comparing the effects of 10 fluoroquinolones and examining the potential of one of these antimicrobial agents, pefloxacin, to induce tendon lesions when coadministered with one of nine anti-inflammatory compounds. Among the 10 fluoroquinolones tested, fleroxacin and pefloxacin were the most toxic, inducing lesions at a dose of 100 mg/kg of body weight or more, while lomefloxacin, levofloxacin, and ofloxacin or sparfloxacin and enoxacin induced lesions at 300 mg/kg or more and 900 mg/kg, respectively. In contrast, norfloxacin, ciprofloxacin, and tosufloxacin had no effect even at the high dose of 900 mg/kg. The severity of the Achilles tendon lesions appeared to correlate with the structure of the substituent at the seventh position. Furthermore, pefloxacin-induced tendon lesions were inhibited by coadministration with dexamethasone and N-nitro-L-arginine methyl ester. Phenidone (1-phenyl-3-pyrazolidinone) and 2-(12-hydroxydodeca-5,10-diynyl)3,5,6-trimethyl-1,4-benzoqui none (AA861) also decreased the incidence of tendon lesions. In contrast, catalase, dimethyl sulfoxide, indomethacin, pyrilamine, and cimetidine did not modify these tendon lesions. These results suggest that nitric oxide and 5-lipoxigenase products partly mediate fluoroquinolone-induced tendon lesions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371338      PMCID: PMC164133     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

1.  Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells.

Authors:  M W Radomski; R M Palmer; S Moncada
Journal:  Proc Natl Acad Sci U S A       Date:  1990-12       Impact factor: 11.205

Review 2.  Nitric oxide: physiology, pathophysiology, and pharmacology.

Authors:  S Moncada; R M Palmer; E A Higgs
Journal:  Pharmacol Rev       Date:  1991-06       Impact factor: 25.468

Review 3.  Eicosanoids in inflammation.

Authors:  G A Higgs; S Moncada; J R Vane
Journal:  Ann Clin Res       Date:  1984

4.  Ciprofloxacin and tenosynovitis.

Authors:  S R McEwan; P G Davey
Journal:  Lancet       Date:  1988-10-15       Impact factor: 79.321

5.  Nitric oxide: a cytotoxic activated macrophage effector molecule.

Authors:  J B Hibbs; R R Taintor; Z Vavrin; E M Rachlin
Journal:  Biochem Biophys Res Commun       Date:  1988-11-30       Impact factor: 3.575

6.  Evidence that endogenous nitric oxide modulates oedema formation induced by substance P.

Authors:  S R Hughes; T J Williams; S D Brain
Journal:  Eur J Pharmacol       Date:  1990-12-04       Impact factor: 4.432

7.  Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo.

Authors:  D D Rees; R M Palmer; R Schulz; H F Hodson; S Moncada
Journal:  Br J Pharmacol       Date:  1990-11       Impact factor: 8.739

8.  Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide.

Authors:  J Stadler; M Stefanovic-Racic; T R Billiar; R D Curran; L A McIntyre; H I Georgescu; R L Simmons; C H Evans
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

9.  Leukotrienes increase blood-brain barrier permeability following intraparenchymal injections in rats.

Authors:  K L Black; J T Hoff
Journal:  Ann Neurol       Date:  1985-09       Impact factor: 10.422

10.  Hepatocytes produce nitrogen oxides from L-arginine in response to inflammatory products of Kupffer cells.

Authors:  R D Curran; T R Billiar; D J Stuehr; K Hofmann; R L Simmons
Journal:  J Exp Med       Date:  1989-11-01       Impact factor: 14.307

View more
  12 in total

1.  Ultrastructure of Achilles tendons of rats treated with ofloxacin and fed a normal or magnesium-deficient diet.

Authors:  M Shakibaei; K Pfister; R Schwabe; J Vormann; R Stahlmann
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Drug-versus-drug adverse event rate comparisons: a pilot study based on data from the US FDA Adverse Event Reporting System.

Authors:  Alan M Hochberg; Ronald K Pearson; Donald J O'Hara; Stephanie J Reisinger
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

3.  [Bilateral Achilles tendinitis as adverse reaction to levofloxacine. Concerning a case].

Authors:  E Vila; A Anguita; M Borrell
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

4.  Stochastic mechanical degradation of multi-cracked fiber bundles with elastic and viscous interactions.

Authors:  Fabio Manca; Stefano Giordano; Pier Luca Palla; Fabrizio Cleri
Journal:  Eur Phys J E Soft Matter       Date:  2015-05-25       Impact factor: 1.890

5.  Bilateral spontaneous non-traumatic rupture of the Achilles tendon: a case report.

Authors:  Zubair Khanzada; Ulfin Rethnam; David Widdowson; Ahmed Mirza
Journal:  J Med Case Rep       Date:  2011-06-30

6.  Pefloxacin-induced achilles tendon toxicity in rodents: biochemical changes in proteoglycan synthesis and oxidative damage to collagen.

Authors:  M A Simonin; P Gegout-Pottie; A Minn; P Gillet; P Netter; B Terlain
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

7.  The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro.

Authors:  S Lim; M A Hossain; J Park; S H Choi; G Kim
Journal:  Vet Res Commun       Date:  2007-11-20       Impact factor: 2.459

8.  Spontaneous bilateral Achilles tendon rupture in a patient treated with oral levofloxacin.

Authors:  A E Salvi; G P Metelli; A Bosco; A Berizzi; S A Hacking; A Cantalamessa
Journal:  J Orthop Traumatol       Date:  2007-06-08

9.  Too Much of a Good Thing: Defining Antimicrobial Therapeutic Targets to Minimize Toxicity.

Authors:  Kevin J Downes; Jennifer L Goldman
Journal:  Clin Pharmacol Ther       Date:  2021-02-27       Impact factor: 6.875

10.  TOL19-001 reduces inflammation and MMP expression in monolayer cultures of tendon cells.

Authors:  Catherine Baugé; Sylvain Leclercq; Thierry Conrozier; Karim Boumediene
Journal:  BMC Complement Altern Med       Date:  2015-07-09       Impact factor: 3.659

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.